189 related articles for article (PubMed ID: 37483001)
21. Dementia with Lewy bodies. Review of diagnosis and pharmacologic management.
Frank C
Can Fam Physician; 2003 Oct; 49():1304-11. PubMed ID: 14594099
[TBL] [Abstract][Full Text] [Related]
22. [Drug treatment of dementia with Lewy bodies and Parkinson's disease dementia--common features and differences].
Drach LM
Med Monatsschr Pharm; 2011 Feb; 34(2):47-52; quiz 53-4. PubMed ID: 21428015
[TBL] [Abstract][Full Text] [Related]
23. Administration of zonisamide in three cases of dementia with Lewy bodies.
Odawara T; Shiozaki K; Togo T; Hirayasu Y
Psychiatry Clin Neurosci; 2010 Jun; 64(3):327-9. PubMed ID: 20408991
[TBL] [Abstract][Full Text] [Related]
24. Combination Therapy with Zonisamide and Antiparkinson Drugs for Parkinson's Disease: A Meta-Analysis.
Matsunaga S; Kishi T; Iwata N
J Alzheimers Dis; 2017; 56(4):1229-1239. PubMed ID: 28157097
[TBL] [Abstract][Full Text] [Related]
25. Zonisamide improves motor function in Parkinson disease: a randomized, double-blind study.
Murata M; Hasegawa K; Kanazawa I;
Neurology; 2007 Jan; 68(1):45-50. PubMed ID: 17200492
[TBL] [Abstract][Full Text] [Related]
26. Increased dosage of donepezil for the management of behavioural and psychological symptoms of dementia in dementia with Lewy bodies.
Manabe Y; Ino T; Yamanaka K; Kosaka K
Psychogeriatrics; 2016 May; 16(3):202-8. PubMed ID: 26179411
[TBL] [Abstract][Full Text] [Related]
27. Donepezil for dementia with Lewy bodies: a randomized, placebo-controlled trial.
Mori E; Ikeda M; Kosaka K;
Ann Neurol; 2012 Jul; 72(1):41-52. PubMed ID: 22829268
[TBL] [Abstract][Full Text] [Related]
28. Zonisamide for DLB parkinsonism: An old drug used in a new context.
Hershey LA; Irwin DJ
Neurology; 2018 Feb; 90(8):349-350. PubMed ID: 29367446
[No Abstract] [Full Text] [Related]
29. A comparison of the efficacy of donepezil in Parkinson's disease with dementia and dementia with Lewy bodies.
Thomas AJ; Burn DJ; Rowan EN; Littlewood E; Newby J; Cousins D; Pakrasi S; Richardson J; Sanders J; McKeith IG
Int J Geriatr Psychiatry; 2005 Oct; 20(10):938-44. PubMed ID: 16163744
[TBL] [Abstract][Full Text] [Related]
30. Levodopa use and sleep in patients with dementia with Lewy bodies.
Molloy S; Minett T; O'Brien JT; McKeith IG; Burn DJ
Mov Disord; 2009 Mar; 24(4):609-12. PubMed ID: 19191343
[TBL] [Abstract][Full Text] [Related]
31. Randomized trial of safinamide add-on to levodopa in Parkinson's disease with motor fluctuations.
Borgohain R; Szasz J; Stanzione P; Meshram C; Bhatt M; Chirilineau D; Stocchi F; Lucini V; Giuliani R; Forrest E; Rice P; Anand R;
Mov Disord; 2014 Feb; 29(2):229-37. PubMed ID: 24323641
[TBL] [Abstract][Full Text] [Related]
32. Comparative efficacy and safety of monoamine oxidase type B inhibitors plus channel blockers and monoamine oxidase type B inhibitors as adjuvant therapy to levodopa in the treatment of Parkinson's disease: a network meta-analysis of randomized controlled trials.
Yan R; Cai H; Cui Y; Su D; Cai G; Lin F; Feng T
Eur J Neurol; 2023 Apr; 30(4):1118-1134. PubMed ID: 36437702
[TBL] [Abstract][Full Text] [Related]
33. Improvement of both psychotic symptoms and Parkinsonism in a case of dementia with Lewy bodies by the combination therapy of risperidone and L-DOPA.
Kato K; Wada T; Kawakatsu S; Otani K
Prog Neuropsychopharmacol Biol Psychiatry; 2002 Jan; 26(1):201-3. PubMed ID: 11853113
[TBL] [Abstract][Full Text] [Related]
34. Levodopa-induced dyskinesia in dementia with Lewy bodies and Parkinson disease with dementia.
Turcano P; Stang CD; Bower JH; Ahlskog JE; Boeve BF; Mielke MM; Savica R
Neurol Clin Pract; 2020 Apr; 10(2):156-161. PubMed ID: 32309034
[TBL] [Abstract][Full Text] [Related]
35. Characterization of symptoms and determinants of disease burden in dementia with Lewy bodies: DEvELOP design and baseline results.
van de Beek M; van Steenoven I; van der Zande JJ; Porcelijn I; Barkhof F; Stam CJ; Raijmakers PGHM; Scheltens P; Teunissen CE; van der Flier WM; Lemstra AW
Alzheimers Res Ther; 2021 Feb; 13(1):53. PubMed ID: 33637117
[TBL] [Abstract][Full Text] [Related]
36. Efficacy and tolerability of entacapone as adjunctive therapy to levodopa in patients with Parkinson's disease and end-of-dose deterioration in daily medical practice: an open, multicenter study.
Durif F; Devaux I; Pere JJ; Delumeau JC; Bourdeix I;
Eur Neurol; 2001; 45(2):111-8. PubMed ID: 11244274
[TBL] [Abstract][Full Text] [Related]
37. Effects of Donepezil on Extrapyramidal Symptoms in Patients with Dementia with Lewy Bodies: A Secondary Pooled Analysis of Two Randomized-Controlled and Two Open-Label Long-Term Extension Studies.
Mori E; Ikeda M; Nakagawa M; Miyagishi H; Yamaguchi H; Kosaka K
Dement Geriatr Cogn Disord; 2015; 40(3-4):186-98. PubMed ID: 26226884
[TBL] [Abstract][Full Text] [Related]
38. Long-term safety and efficacy of donepezil in patients with dementia with Lewy bodies: results from a 52-week, open-label, multicenter extension study.
Ikeda M; Mori E; Kosaka K; Iseki E; Hashimoto M; Matsukawa N; Matsuo K; Nakagawa M;
Dement Geriatr Cogn Disord; 2013; 36(3-4):229-41. PubMed ID: 23949147
[TBL] [Abstract][Full Text] [Related]
39. Efficacy and safety of adjunctive rasagiline in Japanese Parkinson's disease patients with wearing-off phenomena: A phase 2/3, randomized, double-blind, placebo-controlled, multicenter study.
Hattori N; Takeda A; Takeda S; Nishimura A; Kato M; Mochizuki H; Nagai M; Takahashi R
Parkinsonism Relat Disord; 2018 Aug; 53():21-27. PubMed ID: 29748109
[TBL] [Abstract][Full Text] [Related]
40. Effect of levodopa on cognitive function in Parkinson's disease with and without dementia and dementia with Lewy bodies.
Molloy SA; Rowan EN; O'Brien JT; McKeith IG; Wesnes K; Burn DJ
J Neurol Neurosurg Psychiatry; 2006 Dec; 77(12):1323-8. PubMed ID: 16952917
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
